Abstract
77 high risk children 0-12 years old (M=14 months ± 24 S.D.), 40 males and 37 females were selected for active immunisation against hepatitis B. 61 were newborns and infants of HBsAg positive mothers, 16 had father or other HBV carrier relatives. 60 subjects had previously received HBIG and 50/77 were still positive for passive HBsAb at prevaccinal screening. HEVAC B (Pasteur), 5 ug s.c., was given to 22 subjects at T0-T1- T2 months, HBVAX (MSD), 10 ug i.m., was administered to 55/77 at T0 -T1 - T6 months.
Clinical and serologic follow up at 2 years from the beginning of vaccination program showed:
- No complications or important side effects
- No HBV infection
- Protective titers (> 10 mU/ml) in 76/77 subjects after 2 doses (63-12400 mU/ml)
- 1 male “no responder”, another male “hyporesponder” to 3 HBVAX doses and no significant increase of HBsAb titers after the 4th dose in both cases
- Protective titers in the 32 subjects controlled at 2 ys. from the 1st dose of both vaccines and possibility of considering optional the proposed 4th dose of HEVAC B
- Sufficient protection of one HBIG dose, 0,5 ml/Kg, at birth in new - borns vaccinated in the first days of life.
- Apparent better response to active immunisation in passive prophylaxed infants compared with no HBIG treated subjects as observed by Beasley and coll.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gussetti, N., Pornaro, E., Demetri, N. et al. HBV VACCINE IN PAEDIATRIC AGE: LONG TERM OBSERVATIONS. Pediatr Res 19, 1104 (1985). https://doi.org/10.1203/00006450-198510000-00209
Issue Date:
DOI: https://doi.org/10.1203/00006450-198510000-00209